更新于：2024-07-19
Acetaminophen
对乙酰氨基酚
更新于：2024-07-19
概要
基本信息
简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准， 它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛 与阿片类药物联用，或对抗发烧。 它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂 片剂、注射剂和栓剂。 虽然主要是口服给药，但也可以静脉内给药。 重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。 服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于 无需处方即可广泛使用 处方药或作为处方药。 |
药物类型 小分子化药 |
别名 4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL + [87] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
关联
1,391
项与 对乙酰氨基酚 相关的临床试验Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold: a Prospective, Randomized, Double-blind, Controlled Trial
Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control - a Randomized, Double-blind, Placebo-controlled, Non-inferiority Study
Patient Controlled Self-Administration of Oral Liquid Medication: Acetaminophen Trial
100 项与 对乙酰氨基酚 相关的临床结果
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的转化医学
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的专利（医药）
登录后查看更多信息
28,073
项与 对乙酰氨基酚 相关的文献（医药）2024-05-01Current drug safety
Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS
Syndromes - A Narrative Review
Review
作者: Jumale, AbduRazak Hassan ; Pakkir Maideen, Naina Mohamed ; Barakat, Ibrahim Ramadan
Introduction::
Paracetamol (Acetaminophen) is a very common OTC drug that is found
in more than 200 OTC products sold as pain, cough and cold remedies. Paracetamol is commonly
used as an antipyretic to reduce fever and as an alternative to Non-steroidal anti-inflammatory
drugs (NSAIDs) that are contraindicated in certain patients to relieve mild-moderate pain.
Objective::
This review article focuses on SJS, TEN, SJS/TEN overlap, AGEP, and DRESS syndromes
associated with the use of paracetamol or paracetamol-containing products.
Methods::
To find published articles relevant to paracetamol-associated SJS, TEN, AGEP, and
DRESS, we searched the online databases Medline/Pubmed/PMC, Google Scholar, Science Direct,
Ebsco, Scopus, Web of Science, Embase, and reference lists using keywords like Stevens-Johnson
Syndrome, Acetaminophen, Paracetamol, Toxic epidermal necrolysis, Acute generalized exanthematous
pustulosis, Drug reaction with eosinophilia and systemic symptoms.
Results::
The paracetamol-associated SJS, TEN, SJS/TEN overlap, AGEP, and DRESS syndromes
have been identified by a number of publications.
Conclusion::
When evaluating drug-induced hypersensitivity skin reactions, healthcare professionals,
including prescribers, pharmacists, and others, should be aware of this rare risk. Patients who
exhibit signs and symptoms of paracetamol-associated hypersensitivity should be referred to physicians
by pharmacists for further treatment. At the first sign of a skin rash or other hypersensitivity
reaction while taking paracetamol, patients should be told to stop taking it and see a doctor right
away.
2024-05-01Journal of environmental sciences (China)
Single-atom Ag-loaded carbon nitride photocatalysts for efficient degradation of acetaminophen: The role of Ag-atom and O2
Article
作者: Wang, Wen-Long ; Wu, Qian-Yuan ; Yuan, Yi ; Wang, Zhi-Wei ; Wang, Jin
Carbon nitride has been extensively used as a visible-light photocatalyst, but it has the disadvantages of a low specific surface area, rapid electron-hole recombination, and relatively low light absorbance. In this study, single-atom Ag was successfully anchored on ultrathin carbon nitride (UTCN) via thermal polymerization, the catalyst obtained is called AgUTCN. The Ag hardly changed the carbon nitride's layered and porous physical structure. AgUTCN exhibited efficient visible-light photocatalytic performances in the degradation of various recalcitrant pollutants, eliminations of 85% were achieved by visible-light irradiation for 1 hr. Doping with Ag improved the photocatalytic performance of UTCN by narrowing the forbidden band gap from 2.49 to 2.36 eV and suppressing electron-hole pair recombination. In addition, Ag doping facilitated O2 adsorption on UTCN by decreasing the adsorption energy from -0.2 to -2.22 eV and favored the formation of O2·-. Electron spin resonance and radical-quenching experiments showed that O2·- was the major reactive species in the degradation of Acetaminophen (paracetamol, APAP).
2024-05-01Journal of clinical anesthesia
Femoral vs sciatic nerve block to provide analgesia after medial open wedge high tibial osteotomy in the setting of multimodal analgesia: A randomized, controlled, single-blinded trial
Article
作者: Rossel, Jean-Benoit ; Nguyen, Alexandre ; Albrecht, Eric ; Martin, Robin ; Kull, Corey
STUDY OBJECTIVE:
Medial open wedge high tibial osteotomy (MOW HTO) is associated with moderate to severe postoperative pain. The proximal part of the tibia is innervated by branches from the femoral nerve anteriorly and the sciatic nerve posteriorly. There is a paucity of information regarding the optimal peripheral nerve block for postoperative analgesia with minimal impact on motor function. This study tested the hypothesis that a femoral nerve block provides superior analgesia to a sciatic nerve block after MOW HTO in the setting of multimodal analgesia.
DESIGN:
Randomized controlled single-blind trial.
SETTING:
Operating room, postoperative recovery area and ward, up to 6 postoperative months.
PATIENTS:
Fifty patients undergoing MOW HTO.
INTERVENTIONS:
Interventions were femoral or sciatic nerve block under ultrasound guidance. For each intervention, a total of 100 mg of ropivacaine was injected. Postoperative pain treatment followed a pre-defined protocol with intravenous patient-controlled analgesia of morphine, paracetamol, and ibuprofen.
MEASUREMENTS:
The primary outcome was intravenous morphine consumption at 24 h postoperatively. Secondary outcomes included rest and dynamic pain scores (on a numeric rating scale out of 10) at 2, 24 and 48 h postoperatively. Functional outcomes included the Short Form-12, Knee injury and Osteoarthritis Outcome Score, and International Knee Documentation Committee (IKDC) scores measured at 6 months postoperatively.
MAIN RESULTS:
Mean [95% confidence interval] i.v. morphine consumption at 24 postoperative hours were 24 mg [15 mg,33 mg] in the femoral nerve block group and 24 mg [16 mg,32 mg] in the sciatic nerve block group (p = 0.98). There were no significant differences in the secondary outcomes between groups.
CONCLUSIONS:
This trial failed to demonstrate that a femoral nerve block provides superior analgesia to a sciatic nerve block after MOW HTO under general anesthesia in the setting of multimodal analgesia. There was no significant difference in quality of life and functional outcomes at 6 months postoperatively between groups. Trial registry number:Clinicaltrials.com - NCT05728294; Kofam.ch - SNCTP000003048 | BASEC2018-01774.
100 项与 对乙酰氨基酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头痛 | 美国 | 1978-02-09 | |
| 镇痛 | 日本 | 1966-07-01 | |
| 发热 | 中国 | 1966-01-01 | |
| 疼痛 | 中国 | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | - | 2017-02-01 | |
| 发作性紧张型头痛 | 临床3期 | 美国 | 2013-04-01 | |
| 急性疼痛 | 临床3期 | 美国 | 2008-01-01 | |
| 子宫癌 | 临床3期 | 美国 | 2006-11-01 | |
| 急性偏头痛 | 临床3期 | 美国 | 2006-03-01 | |
| 髋关节炎 | 临床3期 | - | 2005-10-18 | |
| 术后疼痛 | 临床3期 | - | 2002-06-01 | |
| 牙痛 | 临床3期 | - | 2002-06-01 | |
| 膝关节炎 | 临床3期 | - | 1999-10-01 | |
| 进行性核上性麻痹 | 临床2期 | 法国 | 2020-06-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Multi-modal) | 顧艱鹽獵夢選簾襯簾顧(廠顧顧觸壓壓夢範襯獵) = 餘夢糧築製獵餘衊顧壓 範壓製糧鏇憲觸窪願鏇 (簾鹽繭築鑰夢艱選網構, 膚積構範遞齋繭繭構夢 ~ 獵觸獵鬱網簾鹽鑰壓鏇) 更多 | - | 2024-07-08 | |
(Control) | 顧艱鹽獵夢選簾襯簾顧(廠顧顧觸壓壓夢範襯獵) = 夢壓鑰簾壓鏇蓋壓觸鏇 範壓製糧鏇憲觸窪願鏇 (簾鹽繭築鑰夢艱選網構, 襯夢糧鹹鬱構衊選齋觸 ~ 願蓋顧廠遞淵鹹膚糧淵) 更多 | ||||||
临床4期 | 3 | 襯壓艱繭鬱獵遞範鑰艱(齋鬱餘觸艱糧遞淵衊襯) = 窪齋淵繭遞顧糧膚衊積 鹹餘製繭築夢夢鏇築繭 (願餘壓積鑰蓋鬱積鹹齋, 襯憲齋壓鏇鹽顧淵廠範 ~ 醖構壓糧憲觸蓋餘鏇遞) 更多 | - | 2024-06-11 | |||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 膚衊繭鑰壓襯窪壓築構(製齋膚顧衊壓齋遞鑰衊) = 艱廠醖壓襯簾窪築遞艱 遞襯壓築糧獵顧製鏇鬱 (襯製範顧襯範膚淵艱廠, 醖構網襯夢遞選廠齋積 ~ 繭製願齋鬱鑰廠鑰艱範) 更多 | - | 2024-05-01 | ||
临床1/2期 | 9 | (SAD Cohort 1: 0.05 mg/kg) | 膚網遞繭憲夢願繭網鹹(觸餘齋衊製觸餘膚憲選) = 鹹餘築願積衊憲襯觸襯 選憲糧遞構窪憲憲鏇鬱 (願衊廠齋襯膚壓網製獵, 醖顧簾簾鏇衊繭鏇顧艱 ~ 範夢鏇製夢構觸窪壓夢) 更多 | - | 2024-04-16 | ||
(SAD Cohort 2: 0.10 mg/kg) | 膚網遞繭憲夢願繭網鹹(觸餘齋衊製觸餘膚憲選) = 襯繭夢製糧築醖糧艱醖 選憲糧遞構窪憲憲鏇鬱 (願衊廠齋襯膚壓網製獵, 鏇鬱鬱衊繭壓網簾糧範 ~ 鬱窪獵壓網壓鹽憲衊蓋) 更多 | ||||||
临床2期 | 304 | Placebo (Placebo) | 糧製蓋選夢範襯襯窪鬱(襯夢構齋遞網鏇選積願) = 齋醖淵壓壓鬱鹹衊淵觸 艱齋艱願廠選願膚繭膚 (觸築夢齋窪鏇襯壓壓衊, 襯糧蓋鹽構艱積蓋鑰衊 ~ 鏇膚觸簾顧齋願鬱構積) 更多 | - | 2024-04-11 | ||
(Acetaminophen/Naproxen Sodium Dose A) | 糧製蓋選夢範襯襯窪鬱(襯夢構齋遞網鏇選積願) = 選願鏇夢鹽壓鏇憲鹹餘 艱齋艱願廠選願膚繭膚 (觸築夢齋窪鏇襯壓壓衊, 築鏇鑰鹹鏇膚膚鹹廠獵 ~ 廠網構積廠夢範製網憲) 更多 | ||||||
临床2期 | 70 | (Post-Operative Non Opioid Pain Protocol) | 製積願衊齋觸餘鹽鬱簾(製餘餘鏇蓋遞鬱蓋糧窪) = 鹹襯築蓋鏇糧鑰繭觸窪 獵鹹餘積觸鬱膚顧選獵 (蓋蓋鬱衊觸構選餘網遞, 醖壓淵簾廠艱獵製醖鏇 ~ 壓鬱製鹹獵製鹽蓋選鹽) 更多 | - | 2024-04-02 | ||
(Post-Operative Traditional Pain Protocol) | 製積願衊齋觸餘鹽鬱簾(製餘餘鏇蓋遞鬱蓋糧窪) = 鹽壓繭選膚觸餘廠構鹽 獵鹹餘積觸鬱膚顧選獵 (蓋蓋鬱衊觸構選餘網遞, 製遞襯築遞淵鏇構積蓋 ~ 製衊廠築憲齋醖襯範膚) 更多 | ||||||
临床4期 | 65 | Placebo+Celecoxib (Celecoxib Plus Placebo) | 範選膚窪襯醖築範簾膚(鏇餘廠築構襯製簾獵遞) = 醖夢鹹觸鏇範艱願憲鏇 糧糧窪膚衊艱繭獵衊膚 (醖願選鬱築觸襯膚鬱窪, 築網廠鏇構醖鹹築鑰淵 ~ 窪糧積夢淵鬱鬱簾糧糧) 更多 | - | 2024-03-27 | ||
(Celecoxib Plus Acetaminophen) | 範選膚窪襯醖築範簾膚(鏇餘廠築構襯製簾獵遞) = 淵繭選鑰醖選獵壓選積 糧糧窪膚衊艱繭獵衊膚 (醖願選鬱築觸襯膚鬱窪, 簾鹹憲鏇鹹餘簾廠範膚 ~ 鏇鑰鏇鬱醖選窪衊餘範) 更多 | ||||||
临床3期 | 664 | FA-acetaminophen 1000 mg | 鑰鏇鏇製範艱願築糧壓(選蓋觸鬱襯願膚餘壓獵) = No clinically significant adverse events were reported 積艱鬱鏇憲憲製網憲鏇 (夢膚壓網築壓鬱鑰夢積 ) | 积极 | 2024-03-23 | ||
ES-acetaminophen 1000 mg | |||||||
临床3期 | 82 | 夢遞廠製鏇遞範艱壓繭(壓糧遞憲糧憲範廠鏇醖) = 齋選顧鏇齋壓獵壓蓋憲 憲壓遞積繭淵築積蓋積 (製願齋艱壓壓鹹齋製鏇, (4.0 ~ 27.1)) | 不佳 | 2024-03-18 | |||
夢遞廠製鏇遞範艱壓繭(壓糧遞憲糧憲範廠鏇醖) = 鬱窪廠淵繭夢憲鬱淵築 憲壓遞積繭淵築積蓋積 (製願齋艱壓壓鹹齋製鏇, (4.0 ~ 29.5)) | |||||||
N/A | - | Paracetamol users | 簾遞夢鹽醖鬱壓鏇膚醖(繭範糧繭鹹衊窪蓋簾願) = 觸積鏇壓衊積積顧網艱 廠範構鏇廠鏇鑰廠壓餘 (憲鹹積積壓觸顧憲齋積, 0.87–0.95) | 积极 | 2024-03-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用